DIN 58989:2018 Edition

$19.50

Haemostaseology – HPLC-MS methods for the quantification of direct oral anticoagulants (DOAC) – Rivaroxaban

Published By	Publication Date	Number of Pages
DIN	2018-10	24

Guaranteed Safe Checkout

Categories: 11.100.30 - Analysis of blood and urine, DIN

If you have any questions, feel free to reach out to our online customer service team by clicking on the bottom right corner. We’re here to assist you 24/7.
Email:[email protected]

Description

Rivaroxaban [rINN] is an oral, highly selective direct Factor Xa (FXa) Inhibitor and has an anti-coagulatory effect. This standard describes methods for measuring concentrations of the direct oral anticoagulant (DOAC) rivaroxaban in human plasma samples. This document is applicable to developers and manufacturers of rivaroxaban assays, medical laboratories, as well as institutions and commercial organizations performing biomedical research.

Additional information

Published Code	DIN
Published By	Deutsches Institut für Normung
Publication Date	2018-10
Pages Count	24
Language	Germany
Descriptors	Active substances, Biomedical, Blood, Blood coagulation, Blood plasma, Blood taking, Calibration, Definitions, Haemostaseology, High performance liquid chromatography, HPLC, Human medicine, Inhibition, Inhibitors, Laboratory medicine, Mass spectrometry, Measuring techniques, Medical sciences, Medicine, Properties, Quality, Quality control, Quantification, Samples, Drugs
File Size	1.5 MB
ICS Codes	11.100.30 - Analysis of blood and urine

Preview PDF

DIN 58989

$19.50


PDF Format	Searchable	Printable	Preview Now

DIN 58989:2018 Edition

Related products